The cumulative incidence at 14 days has continued to decline in the last week. It is the main thermometer of the pandemic, since it indicates the infections per 100,000 inhabitants in the last two weeks.
In seven days we have gone from 198 cases per 100,000 inhabitants to 131. In other words, we have dropped from high risk to medium risk. A slightly better situation than we had just a year ago: at the beginning of September 2020 the trend was slightly upward, with data that exceeded 200 cases per 100,000 inhabitants.
COVID ‘Map’ by communities
If we analyze the situation by communities we can observe that only the autonomous city of Melilla remains at extreme risk with more than 300 Cumulative Incidence cases.
Another eight communities are at high risk and the majority, 10, have managed to place themselves at medium risk. This is positive data, although still elevated.
Adolescents, the target group of the virus
Currently, with back to school, it is the youngest who worry the most. The age group between 12 and 19 years old, the students who are now joining their study centers, are the ones who have a higher level of contagion.
Within this group, seven territories are at extreme risk. Among them, the youth of Melilla, Cantabria and Extremadura, which continue to have a very high incidence, the highest in the country, above 400 cases.
Vaccination of the third dose begins
Toledo has already begun the inoculation of the third dose of the vaccine, especially indicated for immunosuppressed patients, with around a dozen people. The same protocol has been initiated in Ciudad Real, and it is expected that in the next few days it will be in the rest of the provinces of Castilla-La Mancha.
Galicia has also started the administration of the third dose of the Covid vaccine to the group of immunosuppressed, with the summons of about 50 people (out of a total of 7,500 Galicians who are estimated to be in that situation), and Feijóo has advanced that the forecast is that all, except contraindication, will have received that third dose in the next two weeks.
On the other hand, it has affirmed that, following the recommendations and guidelines of the scientific community, inoculating the third dose to older people will continue to be “valued” and vulnerable people and, when the clinical trial ends and if agreed, the immunization of children under 12 years of age will be carried out.